Optimization of dose and route of administration of the P‐glycoprotein inhibitor, valspodar (PSC‐833) and the P‐glycoprotein and breast cancer resistance protein dual‐inhibitor, elacridar (GF120918) as dual infusion in rats

• Egile Nagusiak: Christopher Rowbottom (Egilea), Alicia Pietrasiewicz (Egilea), Taras Tuczewycz (Egilea), Richard Grater (Egilea), Daniel Qiu (Egilea), Sudarshan Kapadnis (Egilea), Patrick Trapa (Egilea)
• Formatua: Liburua
• Argitaratua: Wiley, 2021-04-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Transporters can play a key role in the absorption, distribution, metabolism, and excretion of drugs. Understanding these contributions early in drug discovery allows for more accurate projection of the clinical pharmacokinetics. One method to assess the impact of transporters in vivo invol...